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Previously, we reported that Bcl-2 was frequently expressed in renal cell carcinoma (RCC) specimens, but p53 mutation was a rare
event. However, it was unclear whether Bcl-2 positivity was associated with the clinicopathological characteristics and prognosis in
RCC. Therefore, we investigated the expression of Bcl-2 protein and its roles in 101 RCC specimens. In addition, the proliferation
index (PI), apoptotic index (AI), caspase-3 and p53 expression were examined. The immunohistochemical method was applied for
Bcl-2, caspase-3 and p53 protein expression. To investigate the proliferation activity and apoptosis of tumour cells, PI and AI were
calculated based on Ki-67 and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labelling (TUNEL)-positive cells,
respectively. Bcl-2 expression was detected in 72 out of 101 (71.3%) specimens. Bcl-2 positivity was inversely correlated with PI
(Po0.0001) and AI (P¼0.0074). Furthermore, Bcl-2 positivity was significantly correlated with better survival (P¼0.0014), and was
associated with lower stage (P¼0.0301) and grade (P¼0.0020). In RCC, frequent Bcl-2 expression was correlated with favourable
character without higher PI and AI. Thus, Bcl-2 expression might be applied as a novel predictor of better prognosis in RCC patients.
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Tumour growth depends on two main factors, cell proliferation
and cell death by apoptosis (Korsmeyer, 1992). Apoptosis is a form
of cell death characterised by morphological, biological and
genetic features. Abnormalities of apoptosis may lead to uncon-
trolled cellular proliferation and ultimately carcinogenesis. Several
studies have reported significant correlations between apoptosis
and prognosis in malignant tumours including lung cancer
(Macluskey et al, 2000), breast cancer (Gonzalez-Campora et al,
2000) and oesophageal cancer (Shibata and Matsubara, 2001).
Renal cell carcinoma (RCC) has unique clinical characteristics.
These include spontaneous metastasis regression after removal of
the original tumour, late metastasis after curative surgery and a
higher resistance to conventional chemotherapy and irradiation.
Thus, it is difficult to predict prognosis based on conventional
factors – stage and grade. There is a strong necessity for more
precise predicting parameters. Previously, three studies reported
the correlation of apoptosis with overall survival of RCC patients
(Tannapfel et al, 1997; Yoshino et al, 2000; Richter et al, 2002), but
these results were controversial. Tannapfel et al (1997) stated that
high apoptotic index (AI) was significantly related to poor
prognosis and high grade of RCC, but others stated that high AI
was significantly related to better prognosis.
The proto-oncogene bcl-2 is implicated in the regulation of cell
death by inhibiting apoptosis, while the tumour–suppressor gene
p53 and caspases are involved in the induction and execution of
apoptosis. Previously, we reported that urothelial transitional cell
cancer is characterised by high expression of bcl-2 and mutant p53
(Watanabe et al, 1994; Bilim et al, 1996, 1998); furthermore, Bcl-2
is frequently expressed in RCC specimens, but p53 mutation is a
rare event in RCC (Tomita et al, 1996). However, it was unclear
whether Bcl-2 positivity was associated with clinicopathological
characteristics and prognosis in RCC. Although Bcl-2 expression
has also been intensively investigated in other studies, its role in
RCC progression and RCC patients prognosis remains controver-
sial (Lipponen et al, 1995; Vasavada et al, 1998; Huang et al,
1999; Sejima and Miyagawa, 1999; Zhang and Takenaka, 2000;
Uchida et al, 2002). Results of these studies are summarised
in Table 1. Therefore, we decided to investigate the expression of
Bcl-2 protein in RCC and clarify its diagnostic and prognostic
significance.
In this study, we investigated the immunohistochemical
expression of Bcl-2, caspase-3 and p53 protein directly involved
in the regulation of apoptosis, Ki67 marker for proliferation,
detected apoptotic cells by TUNEL staining, and evaluated the
relation of these factors to clinicopathological characteristics and
prognosis in patients with RCC. Although Bcl-2 was shown to be
related to decreased survival and malignant potential in urothelial
transitional cell cancer (Bilim et al, 1996), oesophagus cancer (Hsia
et al, 2001), prostate cancer (Bauer et al, 1996) and other cancers,
we demonstrated here that Bcl-2 is an independent favourable
prognostic factor in RCC patients.
MATERIALS and METHODS
Patients
A total of 101 patients (69 men and 32 women, mean age 58 years,
range 36 – 83) with RCC, who underwent partial or radical
nephrectomy between 1991 and 2000 at our institution, were
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ystudied (Table 2). The mean follow-up period was 58.7 months
(range 1 – 161).
Immunohistochemistry
Immunohistochemical staining was performed using the avidin –
biotin peroxidase complex method, as described previously
(Tomita et al, 1993). Briefly, 5mm sections using a cryostat from
frozen tissues were placed on poly-L-lysine-coated slides or silane-
coated slides, and fixed in cold acetone for 10min. The sections
were incubated for 15min in 20% normal sheep serum at room
temperature, followed by avidin and biotin for 10min. The
sections were then incubated with the primary antibodies for 1h
at room temperature, except for Ki-67, which was applied
overnight at 41C. We used the following primary mouse
monoclonal antibodies: anti-human Bcl-2 protein (1/50 dilution,
Dako, Glostrup, Denmark), p53 Ab-2 (1/200 dilution, Oncogene
Research Products, Boston, MA, USA), Caspase-3 (CPP32)Ab-3 (1/
100 dilution, NeoMarkers, CA, USA) and Anti-human Ki-67
antigen (1/100 dilution, Dako). Next, the sections were incubated
with biotinylated sheep anti-mouse immunoglobulin (Amersham,
Buckinghamshire, England) for 15min at room temperature. After
incubation with streptavidin – horseradish peroxidase (HRP)
(Amersham) for 15min at room temperature, the sections were
peroxidase-stained in 0.05% diaminobenzidine tetrahydrochloride
(DAB) in 100ml 50mM Tris-HCL with 0.01% H2O2. They were
finally counterstained with Meyer’s haematoxylin solution (Wako,
Japan) and mounted with Mount-Quick (Daido Sngyo Co., Ltd,
Japan) after dehydration in graded ethanol and xylene.
The proliferation index (PI) was expressed as a percentage of the
Ki-67 positive cells in the tumour cells, with atleast 500 cells
counted on the several fields for each section.
The evaluation of staining were assessed by two observers (V
Bilim and T Itoi), who were blinded to the clinicopathological
characteristics of the patients.
Detection of apoptosis
Apoptotic cells were detected by TUNEL staining (In Situ
Apoptosis Detection Kit, TAKARA, Japan), according to the
manufacturer’s instructions, as described previously (Bilim et al,
2000). The AI was expressed as a percentage of the TUNEL-
positive cells in the tumour cells, with atleast 500 cells counted in
the several fields for each section.
Immunoblotting
Immunoblotting was performed as described previously (Tomita
et al, 1996). Briefly, tissue samples were lysed in lysis buffer (0.1 M
Tris-HCl pH 8.0, 5mM EDTA, 0.15 M NaCl, 1% Triton X, 1mM
aprotinin, 1mM leupeptin and 1mM PMSF). These lysates were
cleared by centrifugation at 15000r.p.m. for 30min at 41C. A
measure of 10mg of each protein was electrophoretically separated
on a 15% SDS – polyacrylamide gel. Immunoblots were blocked
with 10% skimmed milk in TBS at room temperature for 1h
followed by the primary mouse monoclonal antibody: anti-human
Bcl-2 protein (1/200 dilution, Dako, Glostrup, Denmark). Then, the
blots were incubated with biotinylated sheep anti-mouse immu-
noglobulin, followed by incubation with streptavidin – HRP for
1h. Biotin–streptavidin–HRP complexes were detected using the
ECL Western blotting system (Amersham), according to manu-
facturer’s instructions. To confirm that an equal amount of
proteins were applied to each lane, the blots were subjected to
staining for b-actin (Oncogene Science) as a control.
Statistical analysis
All statistical analyses were performed using commercially
available software (StatView 4.5,. Abacus Concepts, Berkeley, CA,
USA). w
2-tests were used to assess the correlation between Bcl-2
expression and clinicopathologic parameters. The Mann –
Whitney U-test was used to analyse the difference in frequencies
of AI and PI between clinicopathological parameters, and the
relation of Bcl-2 expression with AI or PI. Pearson’s correlation
was used to compare AI and PI. The survival curves were
constructed using a Kaplan – Meier analysis, and the differences
between curves were tested using the log-rank test. Cox propor-
tional hazards model was used in univariate and multivariate
analysis. The cutoff values of AI and PI correspond to the mean
values of each of the indices. Values exceeding these cutoffs were
considered high.
Table 1 Studies with regard to Bcl-2 expression in RCC
Author (year) Number of patients Bcl-2 positive
Bcl-2 positive in clear
cell cases Others
Lipponen et al (1995) 104 21/104 (20.2%) NA
a Bcl-2 expression was related to low T category
Tomita et al (1996) 25 17/25 (68.0%) NA
Vasavada et al (1998) 35 33/35 (94.2%) 26/28 (92.9%) Bcl-2 expression was related to high tumour grade
Huang et al (1999) 33 23/33 (69.7%) NA
Sejima (1999) 53 34/53 (64.2%) NA
Zhang (2000) 70 24/70 (34.3%) 19/56 (33.9%)
Uchida et al (2002) 112 52/112 (42.0%) NA
aNot assessed.
Table 2 Patients characteristics
Mean age (range) years 58.0 (38–83)
Male/female 69/32
T stage
T1 43
T2 19
T3 36
T4 3
Grade
13 4
25 8
38
Unknown 1
Histological type
Clear cell 76
Granular cell 7
Spindle cell 3
Pleomorphic 4
Bellini duct 1
Mixed 10
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Expression of Bcl-2, caspase-3 and p53
Bcl-2 was expressed in the cytoplasm of cancer cells (Figure 1A).
The expression of Bcl-2 was detected in 72 of 101 (71.3%) cases. In
contrast, the expression of p53 was detected in only 1 case in the
nuclei and caspase-3 was detected in four cases in the cytoplasm of
cancer cells (Figure 1B). Expression of Bcl-2 was confirmed by
Western blot analysis (Figure 2). The expression of Bcl-2 was
detected more frequently in pT1-2 than pT3-4 (P¼0.0301), and
more frequently in G1-2 than G3 (P¼0.0020, Table 3). Bcl-2-
positive cases showed better prognosis (P¼0.0014, Figure 3A). In
73 cases without metastasis at surgery, Bcl-2-positive cases also
showed better prognosis and no Bcl-2-positive cases died of RCC
(Figure 3B). When we compared each patient group based on T
categories, in pT3-4 cases without metastasis at surgery, there was
a more significant difference in survival between Bcl-2-positive
and -negative cases (Figure 3C). In clear cell tumours which are the
most common type of RCC, the expression of Bcl-2 was detected in
57 out of 76 (75.0%) cases and Bcl-2-positive cases also showed
better prognosis (P¼0.020).
Detection of cell proliferation and apoptosis
Ki67 positivity was detected in the nuclei of cancer cells in all cases
(Figure 1C). The PI ranged from 0.27 to 28.57% (mean 3.68%). The
value of PI was significantly higher in G3 than G1-2 (P¼0.0007)
and T3-4 than T1-2 (P¼0.0037). In 46 cases (45.5%), TUNEL-
positive cancer cells were detected (Figure 1D). TUNEL-positive
nontumour cells including lymphocytes were not counted. The AI
ranged from 0 to 3.26% (mean 0.25%). As well as PI, the value of
AI was significantly higher in G3 than G1-2 (P¼0.0014) (Table 4),
and there was a positive relation between AI and PI (R¼0.600,
Po0.0001). Furthermore, both AI (P¼0.0074) and PI (Po0.0001)
were inversely correlated with Bcl-2 expression (Table 5).
Multivariate analysis
Multivariate analysis was performed for the parameters which had
a significant effect on prognosis using univariate analysis
including Bcl-2 expression, AI, PI, stage and grade. Of the five
parameters, PI (P¼0.0012), stage (P¼0.0004) and grade
(P¼0.0118) had significant effects on prognosis (Table 6). In 73
cases without metastasis at surgery, only Bcl-2 expression had a
significant effect on prognosis (P¼0.0487, Table 7) in multivariate
analysis.
DISCUSSION
Bcl-2 is a proto-oncogene known to be a negative regulator of
apoptosis. It plays a prominent role in cell longevity through
preventing apoptosis. High levels of Bcl-2 protein expression have
been found in many different types of cancer, suggesting a possible
role for Bcl-2 to deregulate apoptosis and promote malignant
tissue transformation. Indeed, in urothelial transitional cell cancer
(Bilim et al, 1998), oesophagus cancer (Hsia et al, 2001) and
prostate cancer (Bauer et al, 1996) cases with Bcl-2 positivity
represent poor prognosis. However, in RCC, several studies have
shown that Bcl-2 positivity was not associated with prognosis
(Lipponen et al, 1995; Vasavada et al, 1998; Huang et al, 1999;
Sejima and Miyagawa, 1999; Zhang and Takenaka, 2000; Uchida
et al, 2002). Unexpectedly, our present study showed that Bcl-2
positivity was associated with better prognosis. Moreover, multi-
variate analysis showed that, in cases without metastasis at
surgery, Bcl-2 expression was an independent predictor of better
prognosis on overall survival: in fact, in this subgroup, no Bcl-2-
positive cases died due to RCC. With regard to correlation between
Figure 1 Immunohistochemical staining of (A) Bcl-2 (No. 101), (B)
caspase-3 (No. 98), (C) Ki-67 (No. 98) of the indicated RCC tissue
samples. (D) TUNEL staining of No. 98 sample; arrowheads point at some
of TUNEL-positive nuclei. Scale bar is 100mm.
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(1995) stated that Bcl-2 expression was related to low T category
(Table 1). The present study also showed that Bcl-2 positivity was
associated with low stage. However, Vasavada et al (1998) reported
that high Bcl-2 expression showed a significant correlation with
higher tumour grade (Table 1). Our findings were opposite to their
observations. The reason is unknown; however, it may be
explained by the number of cases or methods used including
primary antibodies. They investigated a small subgroup including
only 28 clear and seven papillary renal cell carcinoma cases
(Table 1, Vasavada et al, 1998); on the other hand, we investigated
a larger number of patients. To comfirm the specificity of the
staining, Bcl-2 expression was analysed by Western blot. Indeed, in
breast cancer (Kymionis et al, 2001; Sjostrom et al, 2002) and
thyroid carcinoma (Viale et al, 1995), Bcl-2 positivity also showed
a favourable outcome. These findings were unexpected based on in
vitro data that comfirmed an antiapoptotic role for Bcl-2. Bcl-2 has
been suggested to play an important role in tumorigenesis of RCC,
because previous studies including our own reported that bcl-2
expression was seen in the majority of RCC; however, the results of
the present study suggest an association of Bcl-2 expression with a
less aggressive phenotype of RCC.
To gain further insight into the role of Bcl-2 in RCC and its
relation with better prognosis, we analysed AI, PI and the
expression of caspase-3, p53 and correlations between Bcl-2
expression and these parameters. Bcl-2 expression was signifi-
cantly associated with low AI. Furthermore, three of four cases
with caspase-3 expression were Bcl-2 negative with high AI.
Although only four of 101 specimens were caspase-3 positive,
this might suggest caspase-3 involvement in apoptosis of tumour
cells without Bcl-2 expression. Regarding the correlation between
Bcl-2 expression and tumour-proliferative activity, an inverse
correlation between them was reported in breast (Bozzetti et al,
1999), lung (Ishida et al, 1997) and endometrial carcinomas
(Kuwashima et al, 1997). In the present study, Bcl-2 expression
was also associated with low PI, which implies that Bcl-2
might be a negative controller of proliferation in RCC. This
hypothesis was supported by previous findings that showed
that Bcl-2 inhibited cell proliferation using bcl-2 trangenic mice
(Pierce et al, 2002). Moreover, in the present study, there was a
significant positive relation between AI and PI, and the result was
Figure 2 Western blotting analysis for Bcl-2 in normal kidney and RCC.
Actin was applied as a control for loading.
Table 3 Correlation of Bcl-2 expression with stage or grade
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Figure 3 (A) Disease-specific survival of all cases according to Bcl-2
expression. (B) Disease-specific survival of curatively operated cases
according to Bcl-2 expression. (C) Disease-specific survival of pT3-4 cases
with curative operatation according to Bcl-2 expression.
Bcl-2 as a factor of better prognosis in RCC
T Itoi et al
203
British Journal of Cancer (2004) 90(1), 200–205 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yconsistent with previous findings (Tannapfel et al, 1997; Zhang
and Takenaka, 2000).
The following model is suggested to the present findings. RCC
with a high rate of cell proliferation progresses rapidly to high
stage and grade and results in the patient’s death due to
the disease. At the same time, such RCC demonstrates a high
rate of spontaneous apoptosis due to accumulation of genetic
alterations, hypoxia inside the tumour and other factors. Bcl-2
prevents both cell proliferation (Pierce et al, 2002) and apoptosis.
Thus, Bcl-2-positive tumours may be slow growing and so
possess less malignant potential. On the other hand, Bcl-2
as an antiapoptotic molecule protects tumour cells from
induced apoptosis and may render RCC resistant to all kinds
of apoptotic–triggering therapeutics, including chemotherapy and
irradiation.
In conclusion, Bcl-2 expression may be a novel prognostic factor
for better outcome of RCC patients. In cases without metastasis
at surgery, Bcl-2 expression is an independent predictor of better
prognosis.
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